Management of psoriasis in patients with inflammatory bowel disease: From the Medical Board of the National Psoriasis Foundation - 13/01/18
Abstract |
Background |
There is a significant association between psoriasis and inflammatory bowel disease (IBD). Many treatments for psoriasis and psoriatic arthritis are also used for IBD.
Objective |
To assess therapeutic options for patients with psoriasis and concurrent IBD.
Methods |
A systematic literature search was performed for clinical studies of biologic and systemic psoriasis medications in psoriasis, psoriatic arthritis, ulcerative colitis, and Crohn's disease, for the period from January 1, 1947, to February 14, 2017. Randomized, controlled, double-blinded studies were selected if available. If not, the next highest level of available evidence was selected.
Results |
Of the 2282 articles identified, 132 were selected. Infliximab and adalimumab have demonstrated efficacy in psoriasis, psoriatic arthritis, ulcerative; colitis, and Crohn's disease. Ustekinumab has demonstrated efficacy in psoriasis, psoriatic arthritis, and Crohn's disease. Certolizumab has demonstrated efficacy in psoriatic arthritis and Crohn's disease. Etanercept, secukinumab, brodalumab, and ixekizumab have demonstrated efficacy in psoriasis and psoriatic arthritis but may exacerbate or induce IBD. Guselkumab has demonstrated efficacy in psoriasis.
Limitations |
There are no known clinical trials of treatment specifically for concurrent psoriasis and IBD.
Conclusions |
Infliximab and adalimumab have demonstrated efficacy in psoriasis, psoriatic arthritis, ulcerative colitis, and Crohn's disease; other agents have demonstrated efficacy for some, but not all, of these indications.
Le texte complet de cet article est disponible en PDF.Key words : Crohn's disease, IBD, inflammatory bowel disease, psoriasis, psoriatic arthritis, ulcerative colitis
Abbreviations used : IBD, IL, FDA, TNF
Plan
Funding sources: None. |
|
Disclosure: Dr Whitlock's mother has been an advisor for Ranbaxy, Galderma, Valeant, Medicis, and Allergan. Dr Armstrong has been a consultant or investigator for Abbvie, Amgen, Celgene, Janssen, Lilly, Novartis, Pfizer, and Merck. Dr Gottlieb has been an advisor for Amgen, Astellas, Akros, Janssen, Celgene, Bristol-Meyers Squibb, Beiersdorf, Abbvie, TEVA, Actelion, UCB, Novo Nordisk, Novartis, Dermipsor, Incyte, Pfizer, Canfite, Lilly, Coronado, Vertex, Karyopharm, CSL Behring, GSK, Xenoport, Catabasis, Meiji Seika, Takeda, Mitsubishi, Tanabe, Genentech, Baxalta, Kineta, KPI, Crescendo, Aclaris, Amicus, and Reddys, and she has received grants paid to Tufts from Janssen, Amgen, Abbvie, Novartis, Celgene, Pfizer, Lilly, Levia, Merck, Xenoport, Dermira, and Baxalta. Dr Langley has been an investigator, speaker, or advisor for Amgen, Abbvie, Janssen, Celgene, Lilly, Novartis, and Pfizer. Dr Lebwohl is employed by Mount Sinai, which receives research funds from Abbvie, Amgen, Boehringer Ingelheim, Celgene, Lilly, Janssen, Kadmon, AstraZeneca, Novartis, Pfizer, and ViDac. Dr Merola has been a consultant, advisor, speaker, or investigator for Biogen, UCB, Novartis, Momenta, Abbvie, Amgen, Lilly, UCB, Pfizer, Janssen, Kiniksa, Mallinckrodt, and Boehringer. Dr Ryan has been an advisor, consultant, or speaker for Abbvie, Aqua, Reddys, Lilly, Medimetriks, Novartis, UCB, and Regeneron. Dr Siegel is employed by the National Psoriasis Foundation, which receives unrestricted financial support from AbbVie, Amgen, Celgene, Lilly, Janssen, LEO, Mallinckrodt, Novartis, Pfizer, and Valeant. Dr Weinberg has been a speaker or investigator for Abbvie, Amgen, Celgene, Lilly, and Novartis. Dr Wu is an investigator for AbbVie, Amgen, Eli Lilly, Janssen, Novartis, and Regeneron. Dr Van Voorhees has been an advisor or consultant for Celgene, Pfizer, Abbvie, Novartis, Aqua, Dermira, AstraZeneca, Janssen, LEO, Novartis, and Amgen. |
Vol 78 - N° 2
P. 383-394 - février 2018 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?